DDInter1031 DDInter621
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Edoxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenyl salicylate
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Velpatasvir
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Edoxaban may lead to a major life threatening interaction when taken with Reteplase
Edoxaban may lead to a major life threatening interaction when taken with Velpatasvir